Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended July 31, 2001.
Business Overview: Cooper develops, manufactures, and markets healthcare products through two primary segments: CooperVision (CVI), specializing in contact lenses, and CooperSurgical (CSI), focusing on women's healthcare diagnostic and surgical products.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended July 31, 2001 |
9 Months Ended July 31, 2001 |
3 Months Ended July 31, 2000 |
9 Months Ended July 31, 2000 |
|---|---|---|---|---|
| Net Sales | $59,961 | $164,887 | $50,908 | $142,081 |
| Gross Profit | $37,625 | $106,048 | $33,500 | $92,616 |
| Gross Margin | 63% | 64% | 66% | 65% |
| Operating Income | $14,001 | $37,296 | $13,049 | $32,666 |
| Net Income | $10,361 | $25,380 | $8,661 | $19,819 |
| Diluted EPS | $0.67 | $1.68 | $0.59 | $1.37 |
| Cash from Operations (9mo) | $19,939 | $28,407 | ||
| Total Debt | $55,029 | $48,351 | ||
| Cash & Equivalents | $11,268 | $14,608 |
Note: Total Debt includes short-term debt ($9,435) and long-term debt ($45,594) as of July 31, 2001.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18% in the third quarter and 16% for the nine-month period compared to the prior year. CVI sales grew 15% (quarter) and 13% (nine months), while CSI sales grew 28% (quarter) and 26% (nine months).
- Profitability: Operating income rose 7% in the quarter and 14% year-to-date. Diluted EPS increased 14% in the quarter and 20% year-to-date.
- Margins: Consolidated gross margin decreased slightly to 63% (quarter) and 64% (nine months) from 66% and 65% respectively, attributed to nonrecurring charges and product mix shifts.
- Cash Flow: Operating cash flow for the nine months ended July 31, 2001, was $19.9 million, a decrease from $28.4 million in the prior year, primarily due to increased working capital needs for inventory and receivables.
- Acquisitions: Significant cash outflows for acquisitions ($35.9 million) and capital expenditures ($11.8 million) occurred during the nine-month period.
Guidance, Outlook, and Risks
- Outlook: Management expects CVI gross margins to return to approximately 68% in the fourth quarter. CSI margins are expected to return to or surpass 56% as recent acquisitions integrate. The company anticipates an effective tax rate of 31% for the full fiscal year 2001.
- Accounting Changes: The company will adopt SFAS No. 142 effective November 1, 2001, which will cease the amortization of goodwill. Management estimates this could improve diluted EPS in fiscal 2002 by approximately $0.20 if no impairment losses are recognized.
- Liquidity: The company expanded its KeyBank line of credit to $75 million, with $53.5 million available as of July 31, 2001. Management believes existing cash, operating cash flow, and credit facilities are sufficient to fund operations and future acquisitions.
- Risks and Contingencies:
- Litigation: Wesley Jessen Corporation has filed lawsuits in the U.S., England, and France alleging patent infringement regarding CooperVision's opaque contact lenses. The U.S. court denied a preliminary injunction, but the company faces potential damages and injunctions.
- Currency: Weakness in the pound sterling, euro, and Canadian dollar negatively impacted reported international revenue growth.
- Operations: Implementation of a new information system at CVI caused temporary shipping delays of higher-margin toric lenses.
Key Facts for Investor Verification
- Verify the status and potential financial impact of the patent infringement litigation filed by Wesley Jessen Corporation against CooperVision.
- Monitor the adoption of SFAS No. 142 in November 2001 and the results of the required goodwill impairment testing.
- Assess the integration progress of recent acquisitions (CL-Tinters, LuMax, Medscand) and their impact on CSI margins.
- Review the resolution of shipping delays related to the new CVI information system and its effect on Q4 revenue.
- Confirm the company's ability to maintain liquidity given the significant cash outflows for acquisitions ($35.9 million) and capital expenditures ($11.8 million) in the first nine months.